Actively Recruiting

Phase 3
Age: 12Years - 100Years
All Genders
NCT05682378

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

Led by Novartis Pharmaceuticals · Updated on 2026-05-01

195

Participants Needed

52

Research Sites

476 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH who have completed the ORION-16 (CKJX839C12301), ORION-13 (CKJX839C12302), ORION-20 (CKJX839C12303) or ORION-19 (CKJX839C12304) studies.

CONDITIONS

Official Title

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

Who Can Participate

Age: 12Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female participants with a diagnosis of HeFH or HoFH who completed the ORION-16, ORION-13, ORION-20 or ORION-19 studies
  • Participant derived benefit from treatment with inclisiran in the ORION-16, ORION-13, ORION-20 or ORION-19 studies as judged by investigator
Not Eligible

You will not qualify if you...

  • Participants who screen failed or permanently discontinued treatment or study in the feeder ORION-16, ORION-13, ORION-20, or ORION-19 studies
  • Serious safety or tolerability issues related to inclisiran treatment in previous studies
  • Any uncontrolled or serious disease or medical, physical, or surgical condition that may interfere with participation or put the participant at significant risk

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 52 locations

1

Excel Medical Clinical Trials LLC

Boca Raton, Florida, United States, 33434

Completed

2

Icahn School of Med at Mt Sinai

New York, New York, United States, 10029

Active, Not Recruiting

3

Cincinnati Childrens Hospital MC

Cincinnati, Ohio, United States, 45229-3039

Completed

4

Childrens Hosp Pittsburgh UPMC

Pittsburgh, Pennsylvania, United States, 15224

Active, Not Recruiting

5

Primary Childrens Medical Center

Salt Lake City, Utah, United States, 84113

Completed

6

Novartis Investigative Site

Formosa, Formosa Province, Argentina, P3600

Active, Not Recruiting

7

Novartis Investigative Site

Fortaleza, Ceará, Brazil, 60430-275

Active, Not Recruiting

8

Novartis Investigative Site

São Paulo, São Paulo, Brazil, 04023-900

Completed

9

Novartis Investigative Site

São Paulo, São Paulo, Brazil, 05403 000

Active, Not Recruiting

10

Novartis Investigative Site

Québec, Quebec, Canada, G1V 4W2

Active, Not Recruiting

11

Novartis Investigative Site

Prague, Czechia, 128 08

Active, Not Recruiting

12

Novartis Investigative Site

Prague, Czechia, 150 06

Actively Recruiting

13

Novartis Investigative Site

Besançon, France, 25030

Active, Not Recruiting

14

Novartis Investigative Site

Toulouse, France, 31059

Active, Not Recruiting

15

Novartis Investigative Site

Frankfurt am Main, Hesse, Germany, 60590

Active, Not Recruiting

16

Novartis Investigative Site

Freiburg im Breisgau, Germany, 79100

Completed

17

Novartis Investigative Site

Athens, Greece, 115 27

Completed

18

Novartis Investigative Site

Athens, Greece, 185 47

Active, Not Recruiting

19

Novartis Investigative Site

Pécs, Baranya, Hungary, 7623

Completed

20

Novartis Investigative Site

Jerusalem, Israel, 9112001

Active, Not Recruiting

21

Novartis Investigative Site

Ramat Gan, Israel, 5265601

Active, Not Recruiting

22

Novartis Investigative Site

Milan, MI, Italy, 20162

Completed

23

Novartis Investigative Site

Modena, MO, Italy, 41124

Completed

24

Novartis Investigative Site

Roma, RM, Italy, 00161

Completed

25

Novartis Investigative Site

Roma, Italy, 165

Active, Not Recruiting

26

Novartis Investigative Site

Irbid, Jordan, 22110

Active, Not Recruiting

27

Novartis Investigative Site

Beirut, Lebanon, 113-0236

Active, Not Recruiting

28

Novartis Investigative Site

Beirut, Lebanon, 166830

Active, Not Recruiting

29

Novartis Investigative Site

Sungai Buloh, Selangor, Malaysia, 47000

Active, Not Recruiting

30

Novartis Investigative Site

Kuala Lumpur, Malaysia, 59100

Active, Not Recruiting

31

Novartis Investigative Site

Amsterdam, North Holland, Netherlands, 1105 AZ

Active, Not Recruiting

32

Novartis Investigative Site

Rotterdam, South Holland, Netherlands, 3015 GD

Active, Not Recruiting

33

Novartis Investigative Site

Oslo, Norway, 0514

Active, Not Recruiting

34

Novartis Investigative Site

Gdansk, Poland, 80 952

Active, Not Recruiting

35

Novartis Investigative Site

Lodz, Łódź Voivodeship, Poland, 93-338

Completed

36

Novartis Investigative Site

Kemerovo, Russia, 650002

Completed

37

Novartis Investigative Site

Moscow, Russia, 127412

Completed

38

Novartis Investigative Site

Poprad, Slovakia, 058 01

Active, Not Recruiting

39

Novartis Investigative Site

Ljubljana, Slovenia, 1000

Active, Not Recruiting

40

Novartis Investigative Site

Bloemfontein, Free State, South Africa, 9301

Completed

41

Novartis Investigative Site

Cape Town, Western Cape, South Africa, 7130

Completed

42

Novartis Investigative Site

Pamplona, Navarre, Spain, 31008

Active, Not Recruiting

43

Novartis Investigative Site

Oviedo, Principality of Asturias, Spain, 33011

Completed

44

Novartis Investigative Site

A Coruña, Spain, 15001

Completed

45

Novartis Investigative Site

Córdoba, Spain, 14004

Active, Not Recruiting

46

Novartis Investigative Site

Geneva, Switzerland, 1211

Active, Not Recruiting

47

Novartis Investigative Site

Taipei, Taiwan, 111045

Active, Not Recruiting

48

Novartis Investigative Site

Istanbul, Fatih, Turkey (Türkiye), 34098

Active, Not Recruiting

49

Novartis Investigative Site

Adana, Saricam, Turkey (Türkiye), 01330

Active, Not Recruiting

50

Novartis Investigative Site

Ankara, Yenimahalle, Turkey (Türkiye), 06500

Active, Not Recruiting

51

Novartis Investigative Site

Izmir, Turkey (Türkiye), 35100

Active, Not Recruiting

52

Novartis Investigative Site

Middlesex, United Kingdom, UB9 6JH

Active, Not Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

CONTACT

N

Novartis Pharmaceuticals

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies | DecenTrialz